Travere Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application No. 19/253,088 titled ‘Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders.’ The application relates to specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy (IgAN).

Upon issuance, the patent is expected to provide US patent protection for certain methods of using sparsentan in IgA nephropathy until October 2037. Travere Therapeutics stated that the patent is expected to be formally granted following payment of the issue fee and completion of standard USPTO post-allowance procedures.

The company also plans to submit the issued patent for listing in the US Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, shortly after the patent grant.

Filspari (sparsentan) is currently indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. The therapy is also approved to reduce proteinuria in adult and paediatric patients aged eight years and older with Focal Segmental Glomerulosclerosis (FSGS) without nephrotic syndrome.

IgA nephropathy is a chronic kidney disease caused by the buildup of immunoglobulin A deposits in the kidneys, which can lead to progressive kidney damage and eventual kidney failure. Focal segmental glomerulosclerosis is another rare kidney disorder that affects the kidney’s filtering units and can result in severe protein loss and declining renal function.

Travere Therapeutics said the patent allowance further strengthens its intellectual property portfolio supporting Filspari and reinforces its long-term commitment to addressing unmet medical needs in rare kidney diseases.

The company focuses on identifying, developing and delivering therapies for patients living with rare diseases, working closely with patients, caregivers and the broader rare disease community to improve treatment outcomes and quality of life.